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Abstract: The total damage inflicted on the liver before transplantation is associated with several
surgical manipulations, such as organ recovery, washout of the graft, cold conservation in organ
preservation solutions (UW, Celsior, HTK, IGL-1), and rinsing of the organ before implantation.
Polyethylene glycol 35 (PEG35) is the oncotic agent present in the IGL-1 solution, which is an alterna-
tive to UW and Celsior solutions in liver clinical transplantation. In a model of cold preservation in
rats (4 ◦C; 24 h), we evaluated the effects induced by PEG35 on detoxifying enzymes and nitric oxide,
comparing IGL-1 to IGL-0 (which is the same as IGL-1 without PEG). The benefits were also assessed
in a new IGL-2 solution characterized by increased concentrations of PEG35 (from 1 g/L to 5 g/L)
and glutathione (from 3 mmol/L to 9 mmol/L) compared to IGL-1. We demonstrated that PEG35
promoted the mitochondrial enzyme ALDH2, and in combination with glutathione, prevented the
formation of toxic aldehyde adducts (measured as 4-hydroxynonenal) and oxidized proteins (AOPP).
In addition, PEG35 promoted the vasodilator factor nitric oxide, which may improve the microcircu-
latory disturbances in steatotic grafts during preservation and revascularization. All of these results
lead to a reduction in damage inflicted on the fatty liver graft during the cold storage preservation.
In this communication, we report on the benefits of IGL-2 in hypothermic static preservation, which
has already been proved to confer benefits in hypothermic oxygenated dynamic preservation. Hence,
the data reported here reinforce the fact that IGL-2 is a suitable alternative to be used as a unique
solution/perfusate when hypothermic static and preservation strategies are used, either separately or
combined, easing the logistics and avoiding the mixture of different solutions/perfusates, especially
when fatty liver grafts are used. Further research regarding new therapeutic and pharmacological
insights is needed to explore the underlying mitochondrial mechanisms exerted by PEG35 in static
and dynamic graft preservation strategies for clinical liver transplantation purposes.
Keywords: fatty liver; PEG35; IGL-1 solution; ALDH2; 4-HNE; nitric oxide
1. Introduction
Unhealthy lifestyles associated with alcohol consumption and inappropriate diet,
along with other factors such as aging, are responsible for the accumulation of fat in the
liver, which leads to varying degrees of undesirable hepatic steatosis [1]. Considering the
urgent lack of organs for transplantation, physicians have been obliged to take advantage
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of fatty livers [1,2] to increase the donor pool and thus shorten waiting lists for clinical
transplantation [3]. However, it is clear that steatotic livers show higher vulnerability
against cold ischemia and reperfusion injury [4], and their use increases primary failure
and compromises graft outcome after transplant [4,5].
Ischemic injury in liver transplantation is associated with mechanical organ manip-
ulation by the physician prior to transplantation. The process includes organ recovery,
washing of the graft, cold storage in an organ preservation solution, and finally, rinsing
of the graft. Due to the combined action of ischemia and cold preservation, the graft may
undergo damage. As a result, the cumulative injury in both mandatory steps before trans-
plantation must be minimized in order to achieve the recovery of the graft’s function after
liver transplantation, especially in the case of steatotic grafts [1–4].
The most frequently used preservation solutions for liver transplant are UW, HTK,
Celsior and, more recently, IGL-1 [6,7]. Certain limitations regarding the use of HTK [8,9]
have been pointed out by the United Network for Organ Sharing (UNOS) and the European
Liver Transplant Registry (ELTR). IGL-1 emerged as a good alternative to UW solution,
which is the gold standard [9]. The only differences in their composition are the oncotic
agent (HES for UW and PEG35 for IGL-1) and the reversal of Na+/K+ concentrations
conferring IGL-1 the property of extracellular low potassium solution [10,11]. In addition,
replacing the HES present in UW for PEG35 lessens red blood cell aggregation and favors
organ rinsing, preservation, and perfusion [12]. All these changes in IGL-1 have shown
to provide benefits in clinical liver transplantation in terms of reducing early allograft
dysfunction [13] and improving graft survival according to the European Liver Transplant
Registry (ELTR) [9].
Moreover, PEG35 presence in rinse solution for graft washing out promotes several
cytoprotective factors, conferring hepatoprotection [14]. This includes the generation of
nitric oxide (NO) whose vasodilation properties counterbalance the microcirculation dis-
turbances in fatty liver grafts, favoring graft preservation and revascularization [15–18].
Keeping in mind the beneficial PEG35 properties, we recently proposed the use of IGL-2
solution (containing PEG35) as a suitable perfusate for dynamic hypothermic oxygenated
strategies (HOPE) with promising results [19,20]. This might improve the only perfusate
for machine perfusion currently available, Belzer-MPS and generics, containing HES [21],
given that the use of a unique solution, such as IGL-2, for static preservation and machine
perfusion (MP) would facilitate logistics and avoid the mixture of different solutions [19–21]
when both techniques are combined. This is the criterion by which we evaluated the IGL-2
benefits in static hypothermic preservation in the present study.
Aldehyde dehydrogenase-2 (ALDH2), a liver mitochondrial enzyme that was initially
implicated in the liver alcohol metabolism, has been associated with the pathophysiology of
ischemia–reperfusion injury in several organs, including the liver [22–24]. Several authors
reported that the use of Alda-1 (an activator of ALDH2) protects against liver ischemia–
reperfusion injury (IRI) in the rat [25,26], but currently, no evidence exists on the direct
PEG35 effect as a regulator of mitochondrial ALDH2 in cold old ischemic preservation
strategies, although its cytoprotective action was indirectly evidenced when different organ
preservation solutions were used for cold storage of fatty liver grafts [23,24]. ALDH2 could
play a constitutive housekeeping role essential for the development and regulation of
recycling and survival processes as those occurring in cold ischemia preservation [22,27].
With this in mind, we explored the relevance of PEG35 in IGL-2 solution (Table 1) on
ALDH2. In this communication, we demonstrated for the first time how the direct effects
of PEG35 on mitochondrial ALDH2 contribute towards maintaining mitochondrial func-
tionality during ischemia preservation. Mitochondrial ALDH2 could act as a gatekeeper
of ROS overproduction protecting the liver graft from the damaging effects of transient
aldehydes produced [22–24] besides other additives in preservation solutions such as labile
glutathione [28] that play an important role against oxidative stress.
Int. J. Mol. Sci. 2021, 22, 5332 3 of 13
Table 1. Composition of IGL-2 and IGL-1 solutions.






















Osmolarity (mosmol/L) 320 320
Viscosity (cP) 1.2 1.4
The results reported here reveal the superior antioxidant capacity of IGL-2 (due to
ALDH2 combined with increased glutathione content) against the ischemic insult during
graft preservation, presenting an interesting tool to be considered for improving hypother-
mic fatty liver preservation by using static and dynamic approaches.
2. Results
The presence of PEG35 and glutathione (group IGL-1) is determinant for preventing
liver cold ischemic injury (AST/ALT) and mitochondrial damage (GLDH) during fatty
liver graft preservation and the prevention of energy breakdown during cold storage, at
4 ◦C during 24 h. As revealed in Figure 1, a higher ATP content is shown in liver preserved
in IGL-1 solution (containing PEG35 as oncotic agent) than in liver preserved in IGL-0 (the
same solution as IGL-1 but without PEG35).
Since PEG35 in IGL-1 preserved liver mitochondrial status during cold ischemia insult
during experimental models [23], we evaluated its effect on mitochondrial ALDH2 and
compared it to IGL-0 (which is the same as IGL-1 but without PEG35 in its composition). As
shown in Figure 2, PEG35 presence in IGL-1 promoted significant increases in ALDH2, con-
trasting with the significantly lower levels of ALDH2 found in fatty liver grafts preserved
in IGL-0 (without PEG35). (Figure 2).
Considering the relevance of PEG35 concentration according to the previously known
results, we expanded our study to one additional group using IGL-2 solution [19,20].
We focused mainly on parameters relevant to the mitochondria (such as ALDH2) that
regulate other cytoprotective responses. As demonstrated in Table 1, the IGL-2 solution is
mainly characterized by higher concentrations of PEG35 and glutathione when compared
to IGL-1 (Table 1).
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in steatotic livers preserved in IGL-0 (without PEG35) and IGL-1 solutions (PEG35: 1 g/L) vs. SHAM. 
Results are expressed as mean ± SEM (n = 6). Different lowercase letters indicate significant differ-
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Figure 2. ALDH2 expression and 4-HNE protein-adducts (expressed as µg 4-HNE-BSA-adducts/mg 
protein) levels in steatotic livers preserved in IGL-0 (no PEG35) and IGL-1 solutions (PEG35: 1 g/L) 
vs. SHAM. Results are expressed as mean ± SEM (n = 6). Different lowercase letters indicate signifi-
cant differences among treatments p < 0.05. 
Firstly, we analyzed transaminases (AST/ALT) release and mitochondrial damage 
(GLDH), from which the total liver damage could be inferred. As shown in Figure 3, the 
PEG35 presence was a major factor in preventing transaminases and GLDH release with 
a dose-dependent PEG35 tendency. Although no significant differences between IGL-2 
and IGL-1 were observed (except for AST), the presence of PEG35 seems to be a determi-
nant factor in preventing the release of transaminases and GLDH in a dose-dependent 
manner. 
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Firstly, e analyzed transa inases ( ST/ALT) release and itochondrial da age
(GLDH), from which the total liver da age could be inferred. As shown in Figure 3, the
PEG35 presence as a jor fact r in preventing transa inases and GLDH release with a
dose-dependent PEG35 tendency. Although no significant differences between IGL-2 and
IGL-1 were observed (except for AST), the presence of PEG35 seems to be a determinant
fact r in preventing the release of transaminases and GLDH in a dose-dependent manner.
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With this in mind, we evaluated the incidence of PEG35 on the energy breakdown
prevention during cold storage by measuring ATP content in preserved livers. Data re-
ported in Figure 4 revealed higher ATP levels in PEG-containing solutions and evidenced
the PEG35-dependent energy breakdown prevention during cold preservation.
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Figure 4. ATP, Beclin-1, and LC3B in steatotic liver samples for SHAM, IGL-0, IGL-1, and IGL-2
groups. Results are expressed as mean ± SEM (n = 6). Different lowercase letters indicate significant
differences among treatments (one-way ANOVA, p < 0.05).
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Additionally, and considering the cytoprotective autophagy as a recycling mechanism
of nutrients and energy to cope with stress situations existing in cold ischemia condi-
tions [27], we evaluated Beclin-1 and LC3B as autophagy marker [29]. Beclin-1 and LC3B
levels correlated with the tissue ATP levels in preserved livers in IGL-0, IGL-1, and IGL-2.
As shown in Figure 4, there was a significant upregulation of cytoprotective autophagy
in the IGL-2 group compared with the others, which correlated with ATP levels in PEG35
groups, showing a positive tendance in ATP prevention for IGL solutions.
We correlated mitochondrial aldehyde dehydrogenase 2 (ALDH2) with the toxic
aldehydes (4-HNE) and oxidized protein (AOPP) levels. Figure 5 shows an increase in the
expression of the ALDH2 enzyme, which is concomitant with a decrease in the 4-HNE
protein adducts formation, notably decreasing the levels of oxidized proteins going from
IGL-0 to IGL-1 and IGL-2. When comparing IGL-0 and IGL-1, which only differ in the
presence or absence of PEG, it can be seen that ALDH2 is augmented, the 4-HNE protein
adducted, and AOPP decreased solely by the effect of PEG.
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Therefore, to observe the impact of glutathione on the reduction of oxidative stress 
(and not only by PEG35 itself, which happens when comparing IGL-0 and IGL-1), reduced 
glutathione was measured. There was a significant difference of reduced glutathione in 
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Figure 5. ALDH2 expression and levels of AOPP and 4HNE protein adducts in steatotic liver samples for SHAM, IGL-0,
IGL-1, and IGL-2 groups. Results are expressed as mean ± SEM (n = 6). Different lowercase letters indicate significant
differences among treatments (one-way ANOVA, p < 0.05).
Therefore, to observe the impact of glutathione on the reduction of oxidative stress
(and not only by PEG35 itself, which happens when comparing IGL-0 and IGL-1), reduced
glutathione was measured. There was a significant difference of reduced glutathione in
IGL-2 solution, which was to be expected due to its initial increased dosage; however, high
variance in the IGL-1 group might suggest that part of its glutathione (if compared to IGL-0)
might be spared (therefore, not oxidized) due to other antioxidant capacities derived from
PEG35 (Figure 6).
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Figure 6. Reduced glutathione (GSH) in IGL-2 solution compared to IGL-1 and IGL-0 (no PEG35) in
steatotic liver samples. Different lowercase letters indicate significant differences among treatments
(one-way ANOVA, p < 0.05).
Finally, we evaluated the direct effect of PEG35 on NO production and oncotic pressure
to avoid oedema. As shown in Figure 7, we evidenced respective augments in NOx products
and endothelial NO synthase expression levels. Significant (endothelial NO synthase) eNOS
activity and NOx levels were observed for PEG35 groups (IGL-1 and IGL-2). This fact was
correlated with a significant upregulation of mitochondrial ALDH2 expression in these
groups. A positive trend towards increased eNOS expression and NOx levels in IGL-2 vs.
IGL-1 was observed, but statistical differences were not found.
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3. Discussion
It is well known that fatty livers are more susceptible to cold ischemia during preserva-
tion than normal livers. Therefore, the aim of our research was to increase the performance
of their preservation by developing a new solution (IGL-2).
PEG35 is the oncotic agent present in IGL-1 solution [11], and its protective role in
IRI [30], rinse solution [14], and cold storage [23,24] was previously described. It is an
established fact that any preservation solution must contain antioxidants to counteract ox-
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idative stress during IR. Considering this, the IGL-2 benefits reported here for hypothermic
static preservation are consistent with its suitability to be used in HOPE over the currently
used perfusates (Belzer-MPS or its generics) [19,20]. Both reasons constitute a solid basis
for simplifying the logistics and avoiding mixing different solutions when both static and
HOPE need to be combined. This is especially interesting for rescuing fatty liver graft liver
transplantation purposes [21].
PEG35 solutions (IGL-2 and IGL-1) are related to reduced AST/ALT and especially to
GLDH, showing better mitochondrial protection, as previously described [14,19,20]. PEG35
improved mitochondrial machinery and ALDH2 functionality, reducing graft cold ischemic
injury [23,24]. Consequently, this calls for an exploration of the underlying protective mech-
anisms by which PEG35 confers mitochondrial protection on fatty liver grafts preserved in
IGL-1 and IGL-2 solutions whose mechanisms substantially differ from the ones induced
in HOPE [31], where the transient oxygenation during hypothermic preservation is re-
sponsible for maintaining mitochondrial activity function at basal levels. This confirms the
relevance of organ preservation strategies on the mitochondrial status and their subsequent
benefits in liver transplantation, as recently published by Horvath et al. [32].
Recently, it has been reported that aldehyde dehydrogenase 2 ALDH2 activation is
linked to protective mechanisms in several organs, such as the heart, brain, kidney, and
intestine [22,33]. The cardioprotective and neuroprotective role of ALDH2 in myocardial
ischemia–reperfusion has been demonstrated [34], with recent evidence showing that
ALDH2 inhibition alters endothelial functions along with a deterioration of bioenergetic
functions [35]. ALDH2 arises as an important gatekeeper of ROS overproduction, making
the cell more tolerant to it [36]. In fact, the main function of mitochondrial ALDH2 is to
protect mitochondria and cells from the damaging effect of aldehydes (by oxidizing the
substrates into their corresponding non-toxic carboxylic acids), which are involved in the
oxidative stress associated with IRI [22]. Zhang et al. [25] demonstrated that Alda-1, an
ALDH2 activator, protects the liver against warm IRI preventing oxidative stress. In this
sense, our work revealed that the oncotic agent PEG35 could be considered as an enhancer
of mitochondrial ALDH2 upregulation, whose underlying protective mechanisms against
cold ischemic insult have not been assessed in depth [22].
The prevention of liver injury exerted by solutions containing PEG35 contrasts with
the injury observed in livers preserved in IGL-0 (without PEG35) with depleted energetic
levels after 24 h of cold storage. Remarkably, the comparison of IGL-1 to IGL-0, which only
differ in the presence or absence of PEG, suggests that PEG35 by itself leads to an ALDH2
upregulation. This is consistent with the IGL-2 solution, where the augmented PEG35
content further prevented oxidative stress through ALHD2 upregulation and promoted
cytoprotective autophagy.
Nevertheless, the total antioxidant effects of the IGL-2 solution are mediated by
the contribution of ALDH2, besides the antioxidant action of glutathione present as an
additive, which should be considered as well. Thus, the higher IGL-2 antioxidant capacity
compared to that of IGL-1 (due to increased PEG35 and glutathione concentrations) is also
reflected by preventing AOPP and 4-HNE protein adduct formation in PEG35 solutions
(IGL-1 vs. IGL-0) and, even more importantly, with the presence of increased PEG35 and
glutathione content (IGL-2 vs. IGL-1). Indeed, IGl-1 shows more ALDH2 than IGL-0, and
more IGL-2 than IGL-1, suggesting that ALDH2 increases with PEG35 in a concentration-
dependent manner.
In addition, it must be considered that the increased expression of eNOS synthase
increased the hepatoprotection mechanisms during cold preservation [15]. The beneficial
effects of PEG35 on ALDH2 mitochondrial machinery are also increased by the concomi-
tant presence of glutathione to prevent the action of toxic aldehyde adducts (4-HNE) and
lipoperoxide generation [22] associated with hypothermic storage. Alternatively, PEG35,
through the increased e-NOS activation and subsequent NO generation, prevents the micro-
circulatory disturbances that occur in fatty liver graft revascularization [37]. Furthermore,
some of this NO could act as a scavenger of ROS, thus reducing the number of oxidizing
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particles. IGL-2 is a suitable alternative solution for increasing cold graft preservation
strategies when static cold preservation and HOPE need to be combined.
In conclusion, we demonstrated the relevance of the oncotic agent PEG35 in mod-
ulating the redox state through mitochondrial ALDH2, thus reinforcing the protection
mechanisms of fatty liver graft in cold preservation in combination with glutathione. This
could improve the preservation of fatty liver grafts and may help to design new static and
dynamic preservation strategies using PEG-containing solutions/perfusates.
Further, in-depth research should be conducted to clarify the role of mitochondrial
ALDH2 and its direct relationship with polyethylene glycols features as efficient tools for
preventing IRI.
4. Materials and Methods
4.1. Animals
Homozygous (obese (ob)) Zücker male rats aged 16–18 weeks were purchased from
Charles River (Charles River, Lyon, France). They were housed in a temperature-controlled
environment (25 ◦C) with a 12 h light/dark cycle and provided water and standard chow ad
libitum. The rats presented a rate of steatosis between 60% and 70%. All procedures were
carried out according to the EU rules for animal experiments (EC guideline 86/609/CEE)
and were approved by the University of Barcelona’s Ethics Committees for Animal Experi-
mentation (#483/16). The animals underwent general anesthesia with isoflurane inhalation.
4.2. Experimental Groups
Zücker Rats aged (16–18) weeks were divided into three groups. The abdomen was cut
with a midline incision, and following bile duct cannulation, the portal vein and the splenic
and gastroduodenal veins were ligated. After organ recovery, the livers were flushed with
IGL-0, IGL-1, or IGL-2 (Table 1) and stored in each solution for 24 h at 4 ◦C. Animals were
randomly distributed in different groups (n = 6), as follows:
Group 1 (SHAM): Obese Zücker rats underwent transverse laparotomy, and silk ligatures
of right suprarenal and diaphragmatic veins and hepatic artery were performed before
retrieving the liver.
Group 2 (IGL-0 solution): After organ recovery, fatty livers were flushed with 40 mL of
IGL-0 preservation solution and were then stored in IGL-0 at 4 ◦C for 24 h.
Group 3 (IGL-1 solution): After organ recovery, fatty livers were flushed with 40 mL of
IGL-1 preservation solution and were then stored in IGL-1 at 4 ◦C for 24 h.
Group 4 (IGL-2 solution): After organ recovery, fatty livers were flushed with 40 mL of
IGL-1 preservation solution and were then stored in IGL-2 at 4 ◦C for 24 h.
After 24 h of cold preservation or right after surgery (in the case of Sham), liver
samples were rinsed with Ringer’s lactate (20 mL), and samples were taken from the flush.
They were then stored at −80 ◦C for subsequent biochemical determinations.
4.3. Biochemical Analyses
Transaminase Assay
Liver injury was assessed by alanine aminotransferase (ALT) and aspartate amino-
transferase (AST) commercial kits, purchased from RAL (Barcelona, Spain) following the
manufacturer’s instructions. Briefly, 100 mol of effluent washout was added to 1 mL of
substrate provided by the commercial kit. Transaminase activity was measured at 340 nm
using a UV spectrometer.
4.4. Glutamate Dehydrogenase (GLDH) Activity
Mitochondrial damage was measured by GLDH activity, following the manufacturer’s
instructions of the commercial kit purchased from RANDOX (Crumlin, United Kingdom).
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4.5. Energy Metabolism (ATP Breakdown)
The determination of ATP in liver samples homogenized in a perchloric acid solution
was performed using the ATP assay kit for fluorimetry (Sigma Aldrich ATP colorimet-
ric/fluorometric assay kit, Madrid, Spain). The ATP concentration was determined by
the phosphorylation of glycerol, which is a detectable product for the fluorimeter (exci-
tation/emission 535 nm/587 nm) at 37 ◦C and proportional to the amount of ATP in the
sample. Energy breakdown during cold storage was measured through the changes in
ATP levels.
4.6. 4-Hydroxynonenal Protein Adducts Assay
4-Hydroxynonenal (4-HNE) protein adducts were measured in liver homogenate
using the OxiSelect™ HNE Adduct Competitive ELISA Kit (Cell Biolabs, Inc. San Diego,
CA, USA). Liver was homogenized in 10% (w/v) with a Teflon bar in a RIPA solution, (Tris
50 M pH 7.4, 1% Triton 100×, NaCl 150 mM, NaF 5 M, 0.1% sodium dodecyl sulphate, and
1% sodium deoxycholate) with antiprotease solution (aprotinin at 1.7 mg/mL, 2 µg/mL
pepstatin, 2 µg/mL leupeptin and 1 mM phenylmethylsulfonyl fluoride, and sodium
orthovanadate at 1 mM). The suspension was centrifuged at 2000 g for 5 min and the pellet
discarded. Liver homogenates were added to an HNE conjugate preabsorbed ELISA plate.
After a brief incubation, an anti-HNE polyclonal antibody was added, followed by an
HRP conjugated secondary antibody. The quantity of HNE adduct in protein samples was
determined by comparing its absorbance with that of a known HNE-BSA standard curve.
4.7. Advanced Oxidation Protein Products (AOPP)
Advanced oxidation protein products (AOPP) are biomarkers of oxidative damage to
proteins, detecting dityrosine-containing and cross-linking protein products. The formation
of AOPP in the liver homogenates was spectrophotometrically measured at 340 nm. Results
were obtained through a standard calibration curve using 100 µL of chloramine-T solution
(0–100 µmol/L). AOPP concentration was expressed in nmol/mg protein. Advanced
oxidation protein products (AOPPs) in the liver were assayed by a modification of Witko-
Sarsat’s method [38].
4.8. Glutathione Analysis
Reduced glutathione (GSH) was measured in the liver extracts using the procedure
previously described [28]. Liver samples were homogenized in cold buffer containing 5 mm
phosphate–EDTA buffer (pH 8.0) and 25% HPO3. The homogenates were ultra-centrifuged
at 100,000× g and 4 ◦C for 30 min, and the resulting supernatant, with the fluorescent
probe o-phthalaldehyde, was used to determine GSH concentration. Fluorescence was
determined at a wavelength emission of 420 nm and excitation at 350 nm. Results are
expressed as GSH nmol/mg protein.
4.9. Nitrite/Nitrate Analysis
NO production in the liver was determined by tissue accumulation of nitrite and
nitrate using a colorimetric assay kit (Cayman, Tallinn, Estonia) according to the manufac-
turer’s instructions.
4.10. Western Blot Analysis
ALDH2, Beclin-1, and LC3B
Separated on 6–15% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) gels, proteins were blotted into poly-vinylidene fluoride (PVDF) membranes (Bio-
Rad, Madrid, Spain) and immunoblotted overnight at 4 ◦C using antibodies against ALDH2
(Abcam, Cambridge, UK. ref: ab133306), Beclin-1 (Sigma Aldrich, San Louis, Missouri, ref:
SAB5700251), and LC3B (Abcam, Cambridge, UK. ref: ab48394). Detection was performed
with anti-IgG-HRP (Santa Cruz Biotechnology, Inc., Heidelberg, Germany). In all cases, the
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chemiluminescence signals were quantified ChemiDoc (Bio-Rad, Madrid, Spain). Both β-
actin (Abcam ref: ab8226) and α-tubulin (Abcam ref: ab7291) were used as loading controls.
4.11. 4-HNE Protein Adducts and eNOS
Liver samples were homogenized in RIPA (50 M Tris (pH 7.4), 1% Triton X-100,
150 mM NaCl, 5 M NaF, 0.1% sodium dodecyl sulfate, and 1% sodium deoxycholate) and
centrifuged for 20 min at 10,000 g. The supernatant was denatured with the addition
of Bromophenol Blue (1/2) and heating at 95 ◦C for 5 min. A total of 50 mg of protein
per sample was loaded onto the 10% agarose gel, and wet blotting was carried out on
a PVDF membrane (Bio-rad, Irvine, CA, USA). The membranes were blocked for 1 h
in Odyssey® Blocking Buffer (LI-COR Biosciences GmbH, Germany) diluted in Tris Base
Buffer (TBS, Tris-buffered saline) (pH = 7.4) with 0.05% Tween (TTBS). The membranes were
incubated overnight with anti-4-hydroxynonenal (4-HNE) protein adducts and anti-eNOS
(BD Biosciences-Europe) antibodies according to the manufacturers’ recommendations.
Detection and analysis were carried out by incubation with secondary fluorescence
(800 W) with the Odyssey® Fc system (LI-COR Biosciences GmbH). To quantify the ex-
pression, Image Studio 5.2.5 software (LI-COR Biosciences) was used, correcting for the
total protein analyzed with the REVERTTM solution (Li-COR Biosciences) according to
the manufacturer’s protocol and expressing the results as a percentage with respect to the
sham group.
4.12. Statistics
Data are expressed as mean ± standard error and were compared statistically by
variance analysis, followed by the Student–Newman–Keuls test using GraphPad Prism
version 8.1.0 for Windows (GraphPad Prism software, San Diego, CA, USA, 2018) and
one-way ANOVA. A level of p < 0.05 was considered significant. Significant differences
between groups are represented with different letters in the graphs. A group labeled with a
letter has significant statistical differences compared to a group labeled with a consecutive
letter with a p < 0.05.
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